e 4031 has been researched along with azimilide in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Keserü, GM | 1 |
| Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Jia, L; Sun, H | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Sen, S; Sinha, N | 1 |
| Kane, KA; McIntosh, MA; Pacini, D; Tanira, M | 1 |
| Gibson, KJ; Groh, WJ; Maylie, JG | 1 |
| Baskin, EP; Lynch, JJ | 1 |
| Bril, A; Cheval, B; Faivre, JF; Forest, MC | 1 |
| Liu, YC; Wu, SN | 1 |
| Hara, M; Kanki, H; Kurita, Y; Mitamura, H; Ogawa, S; Sato, T; Shinagawa, K; Shiroshita-Takeshita, A; Takatsuki, S | 1 |
13 other study(ies) available for e 4031 and azimilide
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Comparison of the cardiac electrophysiologic effects of NE-10064 with sotalol and E-4031 and their modification by simulated ischaemia.
Topics: Animals; Anti-Arrhythmia Agents; Hydantoins; Imidazoles; Imidazolidines; In Vitro Techniques; Myocardial Ischemia; Piperazines; Piperidines; Purkinje Fibers; Pyridines; Sheep; Sotalol | 1994 |
Comparison of the rate-dependent properties of the class III antiarrhythmic agents azimilide (NE-10064) and E-4031: considerations on the mechanism of reverse rate-dependent action potential prolongation.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Electric Stimulation; Guinea Pigs; Heart; Hydantoins; Imidazoles; Imidazolidines; In Vitro Techniques; Male; Myocardium; Patch-Clamp Techniques; Piperazines; Piperidines; Potassium Channels; Pyridines; Time Factors | 1997 |
Differential atrial versus ventricular activities of class III potassium channel blockers.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Function; Ferrets; Heart; Hydantoins; Imidazoles; Imidazolidines; Male; Papillary Muscles; Phenethylamines; Piperazines; Piperidines; Potassium Channel Blockers; Potassium Channels; Pyridines; Sulfonamides; Temperature; Ventricular Function | 1998 |
Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Benzamides; Calcium Channel Blockers; Electric Stimulation; Guinea Pigs; Hydantoins; Imidazoles; Imidazolidines; In Vitro Techniques; Male; Membrane Potentials; Nitrendipine; Papillary Muscles; Piperazines; Piperidines; Potassium Channel Blockers; Pyridines; Random Allocation; Ryanodine; Verapamil | 1998 |
Block of erg current by linoleoylamide, a sleep-inducing agent, in pituitary GH3 cells.
Topics: 8,11,14-Eicosatrienoic Acid; alpha-Linolenic Acid; Amides; Animals; Arachidonic Acid; Arachidonic Acids; Calcium; Calcium Channels, L-Type; Dose-Response Relationship, Drug; Endocannabinoids; Humans; Hydantoins; Imidazoles; Imidazolidines; Infant, Newborn; Linoleic Acids; Membrane Potentials; Neuroblastoma; Patch-Clamp Techniques; Piperazines; Piperidines; Pituitary Neoplasms; Polyunsaturated Alkamides; Potassium Channels; Pyridines; Tumor Cells, Cultured | 2003 |
Preserved effects of potassium channel blockers in the pacing-induced remodeled canine atrium: a comparison between E4031 and azimilide.
Topics: Animals; Atrial Fibrillation; Atrial Function; Cardiac Pacing, Artificial; Dogs; Electric Stimulation; Electrocardiography; Electrodes, Implanted; Female; Hydantoins; Imidazoles; Imidazolidines; Male; Piperazines; Piperidines; Potassium Channel Blockers; Pyridines; Refractory Period, Electrophysiological | 2003 |